Souhaitez-vous accéder aux communiqués récents ?

Garching / Munich, Germany, and Breda, the Netherlands, September 24, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and TerThera BV, a leading...

Garching / Munich, Germany, September 16, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that it will unveil dosimetry data from its...

Basel, Switzerland / Munich, Germany, September 16, 2025 – NUCLIDIUM AG, a clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, today announced that...

Reported Total Revenues of $19.5 million for the second quarter of 2025, exceeding the high end of the Company’s guidance range of between $17 million and $19 millionSERB Pharmaceuticals to acquire...

Proceeds will fund further clinical development of the company’s true theranostic pipeline and expansion of the global production and manufacturing network for copper-based...

61Cu-NuriPro™ detected more lesions up to 4 hours post-administration in 50% of patients, not visualized by 18F-piflufolastat PET1,2 Dosimetry data highlight favorable tumor-to-background ratio with...

New study arm (Part D) is part of the broad clinical development plan of the ITM-91/ITM-94 theranostic program in patients with Carbonic Anhydrase IX (CAIX)-expressing tumors Part D builds on...

MP0726, a Radio-DARPin candidate targeting mesothelin (MSLN) and intended for the treatment of ovarian cancer, is nominated for development under strategic partnership with Orano MedPromising tumor...

Boston, June 17, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, the “Radiopharmaceuticals: Technologies and Global Markets” is expected to grow from $10.3 billion in 2024...

Garching / Munich, Germany, and Grenoble, France, June 16, 2025 – ITM Isotope Technologies Munich SE (ITM) and the Institut Laue-Langevin (ILL), today announced an extension of their collaboration for...